Findings

What do systematic reviews say?

68 questions · 68 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 22.1%GRADE not reported 5 · 7.4%Very low 2 · 2.9%Low 9 · 13.2%Moderate 27 · 39.7%High 10 · 14.7%

Intervention not reported

Asthma‐related SAEs ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2039(2 RCTs)

The intervention showed no clear difference in asthma‐related SAEs ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants:… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.86 [0.41, 1.8]
2 studies · 2039 participants
High

Intervention not reported

CFB in ACQ at 3 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 768(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

CFB in ACQ at 3 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 764(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3 participants
Low

Intervention not reported

Asthma‐related SAEs ‐ HD‐ICS/LABA vs MD‐ICS LABA№ of participants: 6244(6 RCTs)

The intervention showed no clear difference in asthma‐related SAEs ‐ HD‐ICS/LABA vs MD‐ICS LABA№ of participants:… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.33 [0.8, 2.21]
6 studies · 6244 participants
High

Intervention not reported

CFB in ACQ at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1961(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1952(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 6 participants
Moderate

Intervention not reported

Severe exacerbations ‐ HD‐ICA/LABA vs MD‐ICS LABA№ of participants: 4492(5 RCTs)

The intervention showed no clear difference in severe exacerbations ‐ HD‐ICA/LABA vs MD‐ICS LABA№ of participants:… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.49 [0.74, 3.01]
5 studies · 4492 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1366(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1379(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

CFB in AQLQ at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1071(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Moderate

Intervention not reported

CFB in AQLQ at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1088(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Moderate

Intervention not reported

CFB in ACQ at 3 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2450(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2450 participants
Moderate

Intervention not reported

CFB in ACQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3762(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 6 participants
Moderate

Intervention not reported

CFB in AQLQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 1223(1 RCT)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6 participants
Moderate

Intervention not reported

CFB in ACQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3152(3 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 12 participants
Low

Intervention not reported

ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3063(3 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.09 [0.99, 1.19]
3 studies · 6 participants
Low

Intervention not reported

ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1916(2 RCTs)

It is very uncertain whether the intervention changes ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.11 [0.91, 1.35]
2 studies · 6 participants
Very low

Intervention not reported

ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1088(1 RCT)

The intervention probably leads to higher ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.08 [1.01, 1.15]
1 study · 12 participants
Moderate

Intervention not reported

CFB in AQLQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2815(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 2222(2 RCTs)

The intervention showed no clear difference in ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.01 [0.95, 1.07]
2 studies · 12 participants
Moderate